Top Markets
Coin of the day
Modalis Therapeutics Corporation Modalis Therapeutics Corporation

Modalis Therapeutics Corporation

4883
Rang in aandelen #29674
Modalis Therapeutics Corporation focuses on discovering and developing... Modalis Therapeutics Corporation focuses on discovering and developing treatments for severe genetic conditions. The company utilizes its proprietary CRISPR-GNDM technology to create therapies by controlling gene expression through the epigenetic modulation of specific genetic loci. Modalis also has a collaborative research agreement with JCR Pharmaceuticals Co., Ltd., aimed at assessing gene therapy drug delivery methods for the central nervous system (CNS), particularly for CNS-related disorders. Founded in 2016, the company was initially known as EdiGENE Corporation before changing its name to Modalis Therapeutics Corporation in August 2019. Its operations are based in Tokyo, Japan.
Aandeelprijs
$0.20877985
Marktkapitalisatie
$20.11M
Verandering (1 dag)
-3.03%
Verandering (1 jaar)
-66.13%
Land
JP
Handel Modalis Therapeutics Corporation (4883)

Categorie

Dividendrendementgeschiedenis voor Modalis Therapeutics Corporation (4883)
Het dividendrendement (TTM) van Modalis Therapeutics Corporation (aandelsymbool: 4883) per 2026 is: 0
Gemiddeld dividendrendement over de afgelopen 5 jaar: 0.00%
Dividendrendementgeschiedenis van Modalis Therapeutics Corporation (4883) van 2026 tot 2026
Dividendrendement aan het einde van elk jaar (TTM)
Jaar Dividendrendement Wijzigen
Niet genoeg gegevens voor de verstrekte datums.
Dividendrendementen (TTM) van vergelijkbare bedrijven of concurrenten